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The CTLA-4 protein is expressed in activated T cells and plays an essential role in the immune response through 
its regulatory effect on T cell activation. Polymorphisms of the CTLA-4 gene have been correlated with autoimmune, 
neoplastic and infectious illnesses. This work aimed to verify possible associations between single nucleotide poly-
morphisms (SNPs) in CTLA-4, -318C/T in the promoter and +49A/G in exon 1 and paracoccidioidomycosis (PCM) 
caused by Paracoccidioides brasiliensis. For this purpose, 66 chronic form PCM patients and 76 healthy controls 
had their allele, genotype and haplotype frequencies determined. The genetic admixture structure of the patients 
and controls was evaluated to eliminate ancestral bias. The comparison of frequencies indicated no significant dif-
ferences between patients and controls that could link the SNPs to PCM. Groups were admixture matched with no 
difference observed in population ancestry inference, indicating that the absence of association between CTLA-4 
polymorphisms and PCM could not be attributed to ancestral bias. This study showed that there was no association 
between the CTLA-4 SNPs -318 and +49 and the resistance or susceptibility to PCM.
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CTLA-4 is an inhibitory receptor expressed tran-
siently on activated CD4+ and CD8+ T lymphocytes and 
constitutively on CD4+CD25+ T regulatory lymphocytes 
(Treg) and a few non-lymphoid cells (Balbi et al. 2007). 
CTLA-4, a receptor structurally homologous to CD28, 
acts as a negative regulator of T cell responses by inter-
acting with B7 molecules on antigen presenting cells; in 
contrast, a costimulatory signal is evoked by CD28-B7 
interaction (Ling et al. 2001, Butty et al. 2007). Anti-
body-mediated blockage of CTLA-4 in vivo has been 
demonstrated to upregulate the immune response in 
murine models of infection, autoimmune disease, tumour 
immunity, allergy and vaccination (Martins et al. 2004, 
Thio et al. 2004). The CTLA-4 gene has been mapped 
to human chromosome 2q33 (Dariavach et al. 1988) and 
consists of four exons that encode a leader sequence and 
extracellular, transmembrane and cytoplasmic domains 
(Harper et al. 1991, Ling et al. 2001). Two main human 
CTLA-4 transcripts have been detected: a full-length 
isoform and a soluble form lacking exon 3 (Harper et 
al. 1991, Ueda et al. 2003, Gough et al. 2005). Various 
single nucleotide polymorphisms (SNPs) in the CTLA-4 
gene have been implicated in susceptibility to autoim-
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mune disorders including Graves disease (Yanagawa et 
al. 1995), type 1 diabetes mellitus (Nisticò et al. 1996), 
celiac disease (Holopainen et al. 2004, van Belzen et 
al. 2004), Addison’s disease (Blomhoff et al. 2004), au-
toimmune thyroid disease (Tomer et al. 2001, Zaletel et 
al. 2006), systemic lupus erythematosus (Barreto et al. 
2004, Lee et al. 2005) and rheumatoid arthritis (Han et 
al. 2005). Other studies also correlated polymorphisms 
in the CTLA-4 gene with neoplastic diseases, such as 
breast cancer (Ghaderi et al. 2004), and infections, such 
as hepatitis B (Thio et al. 2004).
Paracoccidioidomycosis (PCM) is a systemic myco-
sis caused by the thermo-dimorphic fungus Paracoccidi-
oides brasiliensis (Restrepo 1985). It occurs in two differ-
ent forms, the infection (asymptomatic) and the disease 
(symptomatic); the latter can be subdivided into acute (ju-
venile form) and chronic (adult form) (Franco 1987).
Human and experimental PCM evoke a great variety 
of immune responses with a large range of clinical mani-
festations, which depend on the degree of suppression of 
cellular immunity (Bocca et al. 1998, Campanelli et al. 
2003, Cavassani et al. 2006). An imbalance in cytokine 
production, apoptosis-induced cell death and high levels 
of Fas-L and CTLA-4 expression in T cells seem to be 
involved in T cell unresponsiveness. There is increased 
expression of CTLA-4 protein in Treg cells of PCM pa-
tients relative to control groups. In addition, Treg cells 
are present in the lesions and peripheral blood from pa-
tients with the chronic form of PCM, suggesting local 
and systemic regulation of the immune response in this 
illness (Cavassani et al. 2006).
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This study aimed to verify the association between 
CTLA-4 gene polymorphisms and the risk of develop-
ing PCM. Two polymorphisms that cause changes in 
CTLA-4 expression were the target of our study: the 
exon 1 +49A/G polymorphism, which causes a substitu-
tion of alanine for threonine in the 17th position of the 
precursor protein (a substitution in the signal peptide) 
(Nisticò et al. 1996), and the -318C/T polymorphism in 
the promoter region (Deichmann et al. 1996). Individu-
als carrying the A allele of SNP +49 or the T allele of 
SNP -318 have increased expression of CTLA-4 on the 
cell surface (Ligers et al. 2001). The individual biogeo-
graphical ancestry estimate was taken for both patient 
and control groups, as a means to minimize potential 
spurious results attributable to the admixed nature of the 
population sample studied.
PATIENTS, MATERIALS AND METHODS
Human blood samples - Samples from 66 PCM pa-
tients diagnosed with the chronic form (aged 13-70, non-
related males and females) comprised the test group and 
were collected from the southeastern and central-west 
Brazilian regions, both considered endemic areas. The 
control group was made up of 76 volunteers (aged 9-75, 
non-related males and females) from the central-west re-
gion, none of whom had ever contracted PCM. This study 
was approved by the ethical committee of the Brasília 
University and informed consent was obtained from each 
subject or their parent or guardian before sampling.
Genomic DNA extraction - Genomic DNA was ex-
tracted from peripheral blood cells using the DNA extrac-
tion kit GeneCatcher© gDNA Blood Kits (Invitrogen). 
The extracted DNA was quantified using a GeneQuant© 
Pro spectrophotometer (GE Healthcare).
Polymerase chain reaction (PCR) amplification and 
SNP genotyping - The region containing the SNPs (-318C/T 
in the promoter and +49A/G in exon 1) was amplified by 
PCR using the following primer pair designed based on 
sequences retrieved from GenBank (accession M74363): 
P1 forward (5’AGGCTCAGAAGTTAGCAGCCT 3’) 
and P1 reverse (5’CCCTGGAATACAGAGCCAGC 3’). 
PCRs were carried out in reactions containing each prim-
er at 0.1 μM, 10-50 ng of DNA, 25 μL of FideliTaq© (USB 
Corporation) and water to a total volume of 50 μL. The 
PCR program was as follows: initial denaturation at 95ºC 
for 1 min, 28 cycles comprised of 20 sec at 95ºC, 1 min 
annealing at 62ºC and extension for 1 min at 72ºC, and 
a final extension for 5 min at 72ºC. The amplified DNA 
was resolved by electrophoresis in a 1% agarose gel, re-
vealing fragments of approximately 700 bp, as expected. 
Amplicons were purified with the GFX© PCR DNA and 
Gel Band Purification Kit (GE Healthcare) and then sub-
mitted for automatic sequencing on a MegaBACE© 1,000 
(GE Healthcare). The determination of the bases located 
on the -318 and +49 positions of CTLA-4 was done using 
individual electropherogram analysis.
PCR reactions for ancestry markers - An optimised 
PCR was used to co-amplify two multiplex panels of 
ancestry informative markers in DNA samples from 
patients and controls. Afterwards, the PCR-amplified 
products were purified in an enzymatic treatment with 
exonuclease I (Exo I) and shrimp alkaline phosphatase 
to eliminate non-incorporated dNTPs and primers. 
Finally, the minisequencing reaction was performed 
using the SNaPshot® Multiplex minisequencing kit re-
action mix (Applied Biosystems) and the products of 
the SNaPshot® reaction were analysed on an ABI 3130 
XL Genetic Analyser (Applied Biosystems) in an ABI 
3,700 POP-6© polymer. Genotypes were determined 
using GeneScan Analysis Software, version 3.7 (Ap-
plied Biosystems) and Genotyper version 3.7 (Applied 
Biosystems). A detailed, optimized multiplex, single-
base extension protocol, with reagent concentrations 
and PCR thermocycling conditions, was described 
elsewhere (Lins et al. 2007, 2010a).
Statistical analysis - Allele and genotype frequen-
cies were obtained through electropherogram analysis 
by direct counting. Comparisons of genotypes and al-
leles between PCM patients and the control group were 
performed by using χ2 test calculated on 2 × 2 or 2 × 3 
contingency tables and the odds ratio and 95% confi-
dence intervals were calculated as measurements of the 
strength of association, both using the SPSS Data Editor 
software (release 17.0). Deviation from the Hardy-Wein-
berg Equilibrium (HWE) was tested with Pearson’s χ2 
test using the Finneti software (http://ihg2.helmholtz-
muenchen.de/cgi-bin/hw/hwa1.pl). The estimation of 
haplotypes, their frequencies and linkage disequilib-
rium (LD) between SNPs -318 and +49 were calculated 
using the expectative maximization algorithm on the 
Haploview software (Barrett et al. 2005). The associa-
tion between the haplotypes of patients and controls was 
verified with the same software, using a χ2 test with sta-
tistical significance defined by p < 0.05.
Population structure analysis - Samples from PCM 
patients and controls were evaluated for population 
structure to avoid spurious results due to population 
admixture. Sixteen ancestry informative markers with 
large differences in allelic frequency were previously 
selected to estimate genetic admixture (Moreno Lima 
et al. 2007). Genotype data from three ethnic parental 
populations were used to adjust inference in admixed 
population: Sub-Saharan African (120 individuals), Am-
erindian (69 individuals) and European-American (78 
individuals) (Smith et al. 2004, Lins et al. 2010a). The 
evaluation of population structure was performed using 
the Structure 2.1 software by means of Bayesian infer-
ence (Pritchard et al. 2000). The program parameters 
were set to 75,000 for the length of burn-in period and 
35,000 Markov Chain Monte Carlo method extra repeti-
tions, with K varying from 1-10. The model of admix-
ture with correlated allele frequencies among popula-
tions was used.
RESULTS
Analysis of SNPs -318C/T and +49A/G - The CTLA-4 
-318C/T allele and genotype frequency distributions in 
PCM patients (n = 66) and controls (n = 76) are report-
ed in Table I. Both groups had equivalent distributions 
with the most frequent genotype being CC, followed by 
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CT. The TT genotype was not observed in this sample 
in either group. The patient and control genotype fre-
quencies were not significantly different (p > 0.05). No 
deviation from the HWE was observed for genotype 
frequencies in patients or controls. PCM patients and 
controls had similar allelic frequencies. The C allele 
was more frequent than the T allele in both patients and 
controls, without any significant difference in occur-
rence between the groups (p > 0.05).
The distribution of the A and G alleles and geno-
types (AA, AG and GG) at position +49 in exon 1 of the 
CTLA-4 gene in PCM patients and controls is reported 
in Table II. The AA and AG genotypes were more preva-
lent than the GG genotype, with no significant differ-
ence in frequencies between the groups. No deviation 
from the HWE was observed for genotype frequencies 
in patients or controls. Consequently, PCM patients and 
controls had similar frequencies of each allele. The A 
allele was more frequent than G allele in both patients 
and controls, without any significant difference in oc-
currence between the groups (p > 0.05).
Haplotype association between the -318C/T and 
+49A/G SNPs - The haplotypes of PCM patients and 
controls, as well as their respective frequencies, were 
estimated by the Haploview software, which enables the 
assessment of LD patterns between SNPs by means of 
a frequency deviation (D’ value) (Barrett et al. 2005). 
Three haplotypes were identified in patients and con-
trols by the allelic association between SNPs -318 and 
+49: CA, CG and TA. The haplotype distribution and 
respective frequencies in patients and controls are listed 
on Table III. LD was observed between SNPs (i.e., ob-
served haplotype frequencies differed from what was 
expected under the LD hypothesis) and no significant 
difference was observed between haplotype frequencies 
of patients and controls.
Ancestry background in patients and controls - In-
dividual ancestry estimates in the patient and control 
groups were estimated by Bayesian inference using sam-
ple data from three parental populations. The ancestry 
contribution of individuals was grouped into European, 
African and Amerindian clusters. Results show that pa-
tient and control groups respectively had background es-
timates of 72% and 77% European, 13% African in both 
groups and 15% and 10% Amerindian. No significant 
difference was observed using tests of homogeneity of 
means and variances (p = 0.499 and p = 0.992, respec-
tively), confirming the admixture-matched contribution 
of ancestries for the two groups (Figure).
DISCUSSION
The goal of this work was to verify whether the -318C/T 
and +49A/G SNPs, which are known to be associated with 
at CTLA-4 gene expression, were related to PCM suscep-
tibility. No statistically significant connections between 
any of the investigated alleles and genotypes of the CT-
LA-4 gene and PCM could be established by comparison 
of their frequencies in chronic patients and controls.
Experiments with T cells by Wang et al. (2002) 
showed that the -318T allele was associated with higher 
promoter activity and, therefore, increased gene expres-
sion and had a stronger negative regulatory effect on T 
TABLE I
Genotype and allelic distribution with their respective frequencies to -318 promoter position  














(%) P OR 95% CI
Genotypes
CC 57 86 91 72 95 91 0.08 0.35 0.10-1.20
CT 9 14 9 4 5 9 0.08 2.84 0.83-9.71
TT 0 0 0 0 0 0 - - -






n/f (%) p OR 95% CI
Alleles
C 123/93 148/97 0.09 0.37 0.11-1.23
T 9/7 4/3 0.09 2.71 0.81-9.00
CI: confidence interval; f: frequency; f1: observed frequency; f2: expected frequency; n: individuals number; OR: odds ratio; p: 
p value; HWE: Hardy-Weinberg Equilibrium.
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cells by CTLA-4. Recent studies demonstrated that the 
SNP at position +49 of exon 1 also influences T cell 
activation, affecting the inhibition of this process by 
CTLA-4, as the +49G allele resulted in lower protein 
expression and, therefore, more pronounced prolifera-
tion of T cells (Kouki et al. 2000). Some autoimmune 
diseases have been correlated with this polymorphism, 
such as rheumatoid arthritis (Han et al. 2005), type 1 
diabetes (Nisticò et al. 1996) and autoimmune thyroid 
disease (Tomer et al. 2001, Zaletel et al. 2006). 
As reported before, PCM patients present with high-
er levels of CTLA-4 expression than healthy controls, 
which was associated with the immunosuppression ob-
served during the disease. In addition, T cells recovered 
from blood and tissue lesions of chronic patients that had 
more CTLA-4 suggest that the immune response to the 
fungus is regulated at both the local and systemic levels 
(Campanelli et al. 2003).
Currently, there are few reports on CTLA-4 polymor-
phisms in the context of infection. A report by Thio et 
al. (2004) suggested that the +49G allele, alone or linked 
to SNP -1722C, could be related to recovery after hepati-
TABLE II
Genotype and allelic distribution with their respective frequencies to +49 exon 1 position  













(%) p OR 95% CI
Genotypes
AA 29 44 45 36 47 46 0.68 0.87 0.45-1.69
AG 29 44 44 34 45 45 0.92 0.97 0.50-1.88
GG 8 12 11 6 8 9 0.4 1.61 0.53-4.91






n/f (%) p OR 95% CI
Alleles
A 87/66 106/70 0.49 0.84 0.51-1.39
G 45/34 46/30 0.49 1.19 0.72-1.96
CI: confidence interval; f: frequency; f1: observed frequency; f2: expected frequency; n: individuals number: OR: odds ratio; p: 
p value; HWE: Hardy-Weinberg Equilibrium.
TABLE III
Haplotype characterization and their respective frequencies  











CA 57.4 67.1 0.08
CG 36.5 30.3 0.25
TA 6.1 2.6 0.14
observed and expected frequencies deviation = 1; f: frequency; 
p: p value.
Triangle plot of individual ancestry estimates. Each of the three axes 
range from 0-100% at the vertices therefore assigning one population 
to another. The individual ancestry estimates is given by the distance 
of an individual to one of the triangle axis, into which paracoccidi-
oidomycosis patients (black triangle) and controls (gray circles) were 
classified. European ancestry predominates in both admixture-
matched groups.
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tis B virus infection by changing the pattern of negative 
regulation of the immune response caused by CTLA-4. 
The +49G allele was detected more often in individuals 
who recover from hepatitis B infection, indicating that 
it improves the response to that infectious agent. These 
data are consistent with a report by Kouki et al. (2000), 
in which +49G reduces CTLA-4 expression and thus en-
hances the immune response. Recently, Su et al. (2007) 
investigated CTLA-4 polymorphisms and their relation 
to squamous cell carcinoma. The -318T allele was more 
often found in women infected by the human papilloma 
virus than in healthy women, which led them to postu-
late that this SNP could be implicated in the persistence 
of the virus, which causes cervical carcinoma. These 
studies confirm the work by Wang et al. (2002), which 
showed an association between the -318T allele and in-
creased protein expression, leading to suppression of the 
immune response.
In our study, we determined the prevalence of the 
-318C allele, presumably associated with a more effec-
tive response, in both patient and control groups, leading 
us to the conclusion that this SNP is unlikely to affect 
the response to PCM. However, previous studies have 
observed the existence of linkage between the -318 and 
+49 SNPs, suggesting that some haplotypes derived 
from the combination of these SNPs could be involved 
in susceptibility to diseases for which no single locus as-
sociation was observed (Kristiansen et al. 2000, Ligers 
et al. 2001). Therefore, on observing the existence of a 
LD between the studied SNPs (D’ = 1.00), we wanted to 
test the hypothesis that haplotype frequencies differed 
between patient and control groups. Still, no significant 
difference was found.
Polymorphisms in other genes that play a role in the 
immune response, such as cytokines, have been corre-
lated with PCM. These include polymorphisms in IL-10 
(-1082 G/A) and TNF-α (-308 G/A) in PCM patients and 
controls (Bozzi et al. 2006). It was found that the IL-10 
-1082G allele, when homozygous, could be associated 
with an increased risk of contracting the illness. No such 
correlation was found for the polymorphism in TNF-α, 
which was found in higher levels in the serum of PCM 
patients (Silva & Figueiredo 1991).
Although some studies have been published con-
cerning the influence of CTLA-4 on PCM (Bozzi et al. 
2004, Cavassani et al. 2006), this study is the first to 
assess the association of polymorphisms and the fungal 
illness. Notably, population and individual genetic struc-
ture analysis was carried out on the patient and control 
groups. Association studies must include ancestry anal-
ysis to eliminate the possibility of spurious associations 
due to the genetic background of the sample (Lins et al. 
2010b). In our study, European ancestry prevailed in 
both control and patient groups and the means and vari-
ances of population admixture were found to be statisti-
cally homogeneous. This result confirms that our study 
had consistent groups in terms of their admixture pat-
tern and that the absence of a correlation between PCM 
and the CTLA-4 polymorphisms was not due to ancestral 
bias (Rosenberg & Nordborg 2006).
Genotype and allele frequency values for the two CT-
LA-4 SNPs analysed in this study were similar to those 
reported by Guzman et al. (2005). Those authors deter-
mined the frequency of polymorphisms in the CD28, 
ICOS and CTLA-4 genes (in the latter, polymorphisms 
in the -318 and +49 positions) in three ethnic groups 
of healthy Southeastern Brazilians (white, mulatto and 
black). Genotype and allele frequencies found in these 
ethnic groups were similar to those reported here for pa-
tients and controls, further corroborating our results.
More work needs to be done to conclusively prove 
that there is no connection between CTLA-4 and PCM 
patients. The limitation of sample size is an important 
issue, particularly when this study is compared to whole 
genome association studies conducted with thousands 
of cases and controls. Nevertheless, we believe that our 
results provide important information about susceptibil-
ity to PMC; specifically, if CTLA-4 does play a role in 
PMC, then its effect is not strong enough to be detected 
at the statistical power allowed by our sample size. Al-
ternatively, responsiveness to PCM and human suscepti-
bilities to other fungal diseases, might be controlled by a 
huge number of genetic variants, each with a small effect 
on the trait (Carvalho et al. 2010). In this case, the sample 
size, even at whole genome association dimensions, may 
only be effective for identifying rare variants with larger 
effects (Goldstein 2009).
In summary, this work demonstrated that the SNPs 
at positions -318 and +49 of the CTLA-4 gene were not 
related to resistance or susceptibility to PCM in the pres-
ent admixture-matched sample. In view of the complex-
ity of the inflammatory process caused by PCM, we 
cannot exclude the possibility that polymorphisms in 
other genes that regulate the immune response could be 
related to the clinical outcome of the infection. Given the 
importance of the signalling molecules produced over 
the course of infection, the effects of rare variants of oth-
er genes must be investigated. Of particular interest are 
those genes that are responsible for signal transduction 
events in the cells that interact with the fungus and those 
that encode cytokines and other proteins that are cen-
tral to cell activation and regulation of the host response. 
The results of this and future work will contribute to the 
knowledge base for meta-analyses on the association be-
tween CTLA-4 polymorphisms and immune responses 
to chronic infections.
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